Latest News

CDC's recent statement raises concerns about vaccine safety and autism links, igniting debate among health experts and fueling vaccine hesitancy.

Dexcom Smart Basal optimizes basal insulin dosing for type 2 diabetes, enhancing management with personalized recommendations and a 15-day CGM sensor.

The findings from the BATURA clinical trial were presented at the 2025 ACAAI Annual Scientific Meeting.

A recent study reveals diverse long COVID trajectories, highlighting the need for further research to understand symptoms and recovery variability.

The biosimilars can be used to treat osteoporosis- and cancer-related bone loss in certain populations.

The program’s legitimacy rests on transparency, audits, and ensuring benefits reach vulnerable patients.

The research further emphasizes the need for more attention on both chronic kidney disease (CKD) and mental health conditions.

New RSV vaccines for older adults enhance prevention efforts, yet awareness and uptake remain low. Pharmacists play a crucial role in improving vaccination rates.

Natural strategies and OTC options can help manage menopause symptoms, from hot flashes to mood changes, for a smoother transition.

FDA approves daratumumab and hyaluronidase for treating newly diagnosed light chain (AL) amyloidosis, enhancing survival rates and treatment efficacy.

The FDA accelerates approval of sevabertinib for advanced non–small cell lung cancer, showcasing promising efficacy and manageable safety in clinical trials.

The investigational, oral PCSK9 inhibitor has the potential to significantly reduce low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia or patients with heterozygous familial hypercholesterolemia.

Selumetinib gains FDA approval for adults with neurofibromatosis type 1, offering hope for those with inoperable plexiform neurofibromas.

Measles resurges globally, threatening U.S. elimination status; pharmacists play a crucial role in vaccination efforts and outbreak response.

An evaluation of the different dosing and administration regimens of high-dose nitroglycerin for sympathetic crashing acute pulmonary edema.

Guselkumab and paltusotine received FDA approval, Kenvue announced the new Tylenol Precise Pain-Relieving Patch, and a new generic version of mifepristone received the green light from the FDA.

Depemokimab shows significant improvements in asthma symptoms and peak expiratory flow, supporting its twice-yearly use for severe asthma management.

Elinzanetant Showed Smaller Reductions in Bone Mineral Density Than Placebo

Routine multicancer early detection tests significantly improve early cancer diagnoses, reducing late-stage cases and enhancing treatment outcomes.

With this action, Thrombate III has become the first and only antithrombin concentrate approved for adult and pediatric patients with hereditary antithrombin deficiency (hATd).